Glioblastoma Clinical Trial
Official title:
Quantifying Progression of Non-Enhancing Tumor in Patients With Recurrent Glioblastoma Treated With Antiangiogenic Agents
The goal of this clinical research study is to learn if magnetic resonance imaging with magnetic resonance spectroscopy ("MRI/MRS" scanning) can measure any extra growth in the tumor that does not show up on regular MRI images. This study procedure will be performed on patients with recurrent glioblastoma who are either being treated with chemotherapy that blocks blood vessel growth, or will soon begin this type of chemotherapy.
The Study Procedures:
MRI scanning is commonly used to check the status of glioblastoma. In this study, MRI
scanning will also be used to try to better understand how chemotherapy that blocks blood
vessel growth may be affecting the status of the glioblastoma.
The timing of all MRI scans for this study will be done on schedule for routine patient
care. There will not be any extra MRI scans performed, but an MRS portion to the MRI scans
will be added. The MRS results will be used in this study to look at the chemical
differences between the cancerous and normal tissue, in order to try to better understand
how your chemotherapy may be working.
Screening Tests:
Before you can begin this study, you will have "screening tests" to help the doctor decide
if you are eligible to take part in this study. The following tests and procedures will be
performed:
- Blood (about 1 teaspoon) will be drawn for routine tests.
- Women who are able to have children must have a negative blood (about 1 teaspoon)
pregnancy test.
MRI/MRS Scanning:
If you are found to be eligible to take part in this study, you will have an MRI/MRS scan of
the brain. The first of these scans will be performed before the chemotherapy starts (either
before your first cycle of this type of chemotherapy or before your next cycle, depending on
whether you were receiving this type of chemotherapy before the study or not). After that,
an MRI/MRS scan will be repeated at Weeks 8 and 16 after the beginning of chemotherapy.
The MRI/MRS scans will follow the same procedure and use the same MRI scanner machine as a
regular MRI scan, but will take about an additional 10 minutes. You will lie still on your
back with your head placed within the openings of the scanner. A contrast solution, which
helps make the tumor visible, will be given through a needle in your vein. The scanning
procedure should take about an hour at each visit.
The results of the MRI/MRS scans will not be used to affect your course of treatment.
Tissue Collection:
If your regular doctor recommends that the tumor be surgically removed, the surgery will be
discussed with you in detail and you will sign a separate informed consent form for it.
Leftover tissue that was removed during the surgery will be collected and used as part of
this study. The tissue will be used to further check the status of the disease, and it will
be compared with the MRI/MRS images.
Biomarker Testing:
In this study, you will also have blood drawn for biomarker testing. Biomarkers are chemical
"markers" in the blood, other body fluids, or tissue that may be related to the status of
disease and/or the effects of treatment. This blood (about 2 teaspoons each time) will be
drawn before the chemotherapy starts and then every 8 weeks while you are on study. The
blood draws will occur on the same days as the MRI/MRS scanning.
Length of Study Participation:
You will continue having blood drawn for biomarker testing every 8 weeks, unless you stop
taking this type of chemotherapy that blocks blood vessel growth. In that case, you will be
taken off study.
If you do have surgery, your participation in this study will end after the surgery. If you
are unable to have surgery, your participation will end after your last MRI/MRS scan.
This is an investigational study. MRI scanning is an FDA approved and commercially available
procedure for checking the status of glioblastoma. At this time and for this purpose, MRS
scanning is being used in research only.
Up to 18 patients will take part in this study. All will be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05664243 -
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
| Recruiting |
NCT05635734 -
Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT03679754 -
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
|
Phase 1 | |
| Completed |
NCT01250470 -
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
|
Phase 1 | |
| Terminated |
NCT03927222 -
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
|
Phase 2 | |
| Recruiting |
NCT03897491 -
PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03587038 -
OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma
|
Phase 1 | |
| Completed |
NCT01922076 -
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
|
Phase 1 | |
| Recruiting |
NCT04391062 -
Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT03661723 -
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
|
Phase 2 | |
| Active, not recruiting |
NCT02655601 -
Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001
|
Phase 2 | |
| Completed |
NCT02206230 -
Trial of Hypofractionated Radiation Therapy for Glioblastoma
|
Phase 2 | |
| Completed |
NCT03493932 -
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
|
Phase 1 | |
| Terminated |
NCT02709889 -
Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06058988 -
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
|
Phase 2 | |
| Completed |
NCT03018288 -
Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)
|
Phase 2 | |
| Withdrawn |
NCT03980249 -
Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells
|
Early Phase 1 | |
| Not yet recruiting |
NCT04552977 -
A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Terminated |
NCT02905643 -
Discerning Pseudoprogression vs True Tumor Growth in GBMs
|